# GE HealthCare Technologies Inc.: overview

GEHC · Nasdaq · CIK 1932393 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gehc.md) · [Financials](/companies/gehc/financials.md) · [Filings](/companies/gehc/filings.md) · [Insiders](/companies/gehc/insiders.md)

Latest reported revenue: [$5.13bn](/filings/0001932393-26-000031.md) for Q1 FY2026, three months to 2026-03-31, from the 10-Q filed Apr 29, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001932393-26-000031).

## Last eight quarters

| Line item | Unit | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,839](/filings/0001932393-25-000049.md) | [4,863](/filings/0001932393-25-000053.md) | [5,319 d](/filings/0001932393-26-000007.md) | [4,777](/filings/0001932393-26-000031.md) | [5,007](/filings/0001932393-25-000049.md) | [5,143](/filings/0001932393-25-000053.md) | [5,698 d](/filings/0001932393-26-000007.md) | [5,131](/filings/0001932393-26-000031.md) |
| Gross margin | % | [41.4%](/filings/0001932393-25-000049.md) | [41.7%](/filings/0001932393-25-000053.md) | [42.8% d](/filings/0001932393-26-000007.md) | [42.1%](/filings/0001932393-26-000031.md) | [39.6%](/filings/0001932393-25-000049.md) | [38.7%](/filings/0001932393-25-000053.md) | [39.7% d](/filings/0001932393-26-000007.md) | [38.5%](/filings/0001932393-26-000031.md) |
| Operating margin | % | [12.6%](/filings/0001932393-25-000049.md) | [13.9%](/filings/0001932393-25-000053.md) | [15.1% d](/filings/0001932393-26-000007.md) | [13.2%](/filings/0001932393-26-000031.md) | [13.1%](/filings/0001932393-25-000049.md) | [12.7%](/filings/0001932393-25-000053.md) | [14.5% d](/filings/0001932393-26-000007.md) | [10.0%](/filings/0001932393-26-000031.md) |
| Net margin | % | [8.8%](/filings/0001932393-25-000049.md) | [9.7%](/filings/0001932393-25-000053.md) | [13.6% d](/filings/0001932393-26-000007.md) | [11.8%](/filings/0001932393-26-000031.md) | [9.7%](/filings/0001932393-25-000049.md) | [8.7%](/filings/0001932393-25-000053.md) | [10.3% d](/filings/0001932393-26-000007.md) | [7.6%](/filings/0001932393-26-000031.md) |
| Diluted EPS | $ per share | [0.93](/filings/0001932393-25-000049.md) | [1.02](/filings/0001932393-25-000053.md) | not reported | [1.23](/filings/0001932393-26-000031.md) | [1.06](/filings/0001932393-25-000049.md) | [0.98](/filings/0001932393-25-000053.md) | not reported | [0.85](/filings/0001932393-26-000031.md) |
| Free cash flow | $m | [(183) d](/filings/0001932393-25-000049.md) | [652 d](/filings/0001932393-25-000053.md) | [811 d](/filings/0001932393-26-000007.md) | [98.0](/filings/0001932393-26-000031.md) | [8.0 d](/filings/0001932393-25-000049.md) | [483 d](/filings/0001932393-25-000053.md) | [916 d](/filings/0001932393-26-000007.md) | [112](/filings/0001932393-26-000031.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure.

## Last five fiscal years

| Line item | Unit | FY (2021-12-31) | FY (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [17.6](/filings/0001932393-24-000013.md) | [18.3](/filings/0001932393-25-000005.md) | [19.6](/filings/0001932393-26-000007.md) | [19.7](/filings/0001932393-26-000007.md) | [20.6](/filings/0001932393-26-000007.md) |
| Gross margin | % | [40.8%](/filings/0001932393-24-000013.md) | [39.1%](/filings/0001932393-25-000005.md) | [40.5%](/filings/0001932393-26-000007.md) | [41.7%](/filings/0001932393-26-000007.md) | [40.0%](/filings/0001932393-26-000007.md) |
| Operating margin | % | [15.9%](/filings/0001932393-24-000013.md) | [13.8%](/filings/0001932393-25-000005.md) | [12.5%](/filings/0001932393-26-000007.md) | [13.3%](/filings/0001932393-26-000007.md) | [13.4%](/filings/0001932393-26-000007.md) |
| Net margin | % | [12.8%](/filings/0001932393-24-000013.md) | [10.4%](/filings/0001932393-25-000005.md) | [8.0%](/filings/0001932393-26-000007.md) | [10.1%](/filings/0001932393-26-000007.md) | [10.1%](/filings/0001932393-26-000007.md) |
| Diluted EPS | $ per share | [4.95](/filings/0001932393-24-000013.md) | [4.22](/filings/0001932393-25-000005.md) | [3.03](/filings/0001932393-26-000007.md) | [4.34](/filings/0001932393-26-000007.md) | [4.55](/filings/0001932393-26-000007.md) |
| Free cash flow | $bn | [1.4](/filings/0001932393-24-000013.md) | [1.8](/filings/0001932393-25-000005.md) | [1.7](/filings/0001932393-26-000007.md) | [1.6](/filings/0001932393-26-000007.md) | [1.5](/filings/0001932393-26-000007.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gehc/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Dodge & Cox](/funds/200217.md) | 2026-06-30 | $2.42bn | 37,864,164 |  | Added +6,552,100 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $2.40bn | 37,467,843 |  | Added +1,483,516 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $1.90bn | 29,724,359 |  | Added +860,171 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.34bn | 20,861,566 |  | Added +323,090 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.30bn | 20,275,526 |  | Added +1,092,369 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $1.17bn | 18,296,350 |  | Added +10,558,042 |
| [HARRIS ASSOCIATES L P](/funds/813917.md) | 2026-06-30 | $981.3m | 15,329,664 |  | Reduced −265,324 |
| [BARROW HANLEY MEWHINNEY & STRAUSS LLC](/funds/313028.md) | 2026-06-30 | $861.3m | 13,455,814 |  | Added +1,571,226 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $820.8m | 12,871,800 |  | Added +472,165 |
| [HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC](/funds/1164833.md) | 2026-06-30 | $784.2m | 12,250,502 |  | Added +2,282,629 |

## Recent filings

[All 430 filings](/companies/gehc/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-28 | 06:25 ET | [8-K](/filings/0001932393-26-000058.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001932393-26-000058 |
| 2026-09-22 | 16:07 ET | [8-K](/filings/0001932393-26-000053.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001932393-26-000053 |
| 2026-08-18 | 09:03 ET | [8-K](/filings/0001932393-26-000050.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001932393-26-000050 |
| 2026-07-29 | 06:27 ET | [8-K](/filings/0001932393-26-000047.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001932393-26-000047 |
| 2026-07-29 | 06:27 ET | [10-Q](/filings/0001932393-26-000046.md) | Quarterly report, period 2026-06-30 | 0001932393-26-000046 |
| 2026-07-29 | 06:25 ET | [8-K](/filings/0001932393-26-000045.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001932393-26-000045 |
| 2026-07-23 | 16:17 ET | [8-K](/filings/0001932393-26-000039.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001932393-26-000039 |
| 2026-05-11 | 16:51 ET | [8-K](/filings/0001932393-26-000034.md) | 5.07 Shareholder vote results; 8.01 Other events | 0001932393-26-000034 |
| 2026-04-29 | 06:26 ET | [10-Q](/filings/0001932393-26-000031.md) | Quarterly report, period 2026-03-31 | 0001932393-26-000031 |
| 2026-04-29 | 06:25 ET | [8-K](/filings/0001932393-26-000030.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001932393-26-000030 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001932393-26-000007.md), filed Feb 4, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1932393
- Tickers: GEHC
- Exchange: Nasdaq
- SIC code: 3844 X-Ray Apparatus & Tubes & Related Irradiation Apparatus
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 28, 2026, 06:27 ET. No prices; not investment advice.